US Probes Merck's Marketing Of 3 Drugs

Law360, New York (August 8, 2011, 8:41 PM EDT) -- Merck & Co. Inc. disclosed Monday that the U.S. Department of Justice had asked it to turn over documents detailing marketing practices for cancer drugs Temodar and Intron A and hepatitis C drug PegIntron as part of a criminal investigation.

In a quarterly filing with the U.S. Securities and Exchange Commission, the Whitehouse Station, N.J.-based company said the DOJ issued a subpoena seeking information on marketing and selling activities related to the three drugs from January 2004 to the present.

"We're cooperating with the government," Merck...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.